Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

O'Donoghue M. L. , Fazio S., Giugliano R. P. , Stroes E. S. G. , Kanevsky E., Gouni-Berthold I., ...Daha Fazla

CIRCULATION, cilt.139, sa.12, ss.1483-1492, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier


BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.